Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154462 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154418 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL30295961 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL29478950 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL19785503 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL29374178 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154556 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL20807077 | 0.93 | PTPN11 (0.87) | PTPN11KCNH2EGFR | |
| SCHEMBL24233670 | 0.91 | PTPN11 (0.84) | PTPN11KCNH2EGFR | |
| SCHEMBL20807079 | 0.91 | PTPN11 (0.83) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | PTPN11 441/4885KCNH2 3555/4885EGFR 230/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | PTPN11 682/4885KCNH2 4315/4885EGFR 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.